Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
6.32
+0.13 (2.10%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $51.50M in the quarter ending September 30, 2024, with 7.29% growth. This brings the company's revenue in the last twelve months to $201.21M, up 9.88% year-over-year. In the year 2023, Cytek Biosciences had annual revenue of $193.02M with 17.67% growth.
Revenue (ttm)
$201.21M
Revenue Growth
+9.88%
P/S Ratio
4.14
Revenue / Employee
$297,648
Employees
676
Market Cap
814.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
| Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
| Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
| Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
| Dec 31, 2019 | 57.88M | 52.27M | 930.36% |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
| Dec 31, 2007 | Pro | Pro | Pro |
| Dec 31, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| agilon health | 5.59B |
| Castle Biosciences | 311.88M |
| Paragon 28 | 245.00M |
| Avid Bioservices | 150.45M |
| Immatics | 128.82M |
| AbCellera Biologics | 32.96M |
| uniQure | 28.59M |
CTKB News
- 4 weeks ago - Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program - GlobeNewsWire
- 6 weeks ago - Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter - GlobeNewsWire
- 6 weeks ago - Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe - GlobeNewsWire
- 3 months ago - Cytek Announces Resignation of Chief Operating Officer Chris Williams - GlobeNewsWire
- 4 months ago - Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - GlobeNewsWire
- 4 months ago - Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript - Seeking Alpha